Weber Capital Management LLC ADV Makes New Investment in AngioDynamics, Inc. $ANGO

Weber Capital Management LLC ADV acquired a new stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,356,602 shares of the medical instruments supplier's stock, valued at approximately $17,649,392,000. AngioDynamics accounts for approximately 15.0% of Weber Capital Management LLC ADV's holdings, making the stock its 4th largest holding. Weber Capital Management LLC ADV owned 3.28% of AngioDynamics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Goldman Sachs Group Inc. boosted its holdings in AngioDynamics by 9.6% in the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier's stock valued at $2,434,000 after acquiring an additional 22,658 shares during the last quarter. Jane Street Group LLC increased its stake in AngioDynamics by 267.1% during the first quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier's stock worth $439,000 after acquiring an additional 34,054 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of AngioDynamics by 279.5% in the 2nd quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier's stock worth $123,000 after purchasing an additional 9,098 shares during the period. Rhumbline Advisers raised its holdings in shares of AngioDynamics by 4.3% in the 2nd quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier's stock worth $608,000 after purchasing an additional 2,510 shares during the period. Finally, American Century Companies Inc. lifted its stake in shares of AngioDynamics by 15.8% in the 2nd quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier's stock valued at $960,000 after purchasing an additional 13,217 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 6.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Canaccord Genuity Group boosted their target price on AngioDynamics from $16.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, July 15th. Wall Street Zen raised shares of AngioDynamics from a "hold" rating to a "buy" rating in a research report on Saturday. Zacks Research cut shares of AngioDynamics from a "hold" rating to a "strong sell" rating in a research report on Thursday, July 16th. HC Wainwright increased their price target on AngioDynamics from $16.00 to $19.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of AngioDynamics in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $19.50.

AngioDynamics Price Performance

Shares of NASDAQ ANGO opened at $15.75 on Monday. The firm has a market cap of $650.95 million, a PE ratio of -18.10 and a beta of 0.33. AngioDynamics, Inc. has a fifty-two week low of $9.06 and a fifty-two week high of $16.29. The business has a 50 day moving average price of $13.96 and a two-hundred day moving average price of $12.07.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04. The business had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. On average, analysts anticipate that AngioDynamics, Inc. will post -0.25 earnings per share for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source